Olema Pharmaceuticals, Inc. (OLMA) Stock Analysis & Investment Frameworks
Olema Pharmaceuticals, Inc. (OLMA) stock analysis on Invetso. Review Olema Pharmaceuticals, Inc.’s key financial metrics, company overview and 10 institutional-grade investment frameworks including SWOT Analysis, Economic Moat, Porter’s Five Forces and the Invetso Quality Score.
Olema Pharmaceuticals, Inc. Company Overview
- Exchange: NASDAQ Global Select
- Sector: Healthcare
- Industry: Biotechnology
- Country: US
Olema Pharmaceuticals, Inc. Key Financial Metrics
- Market Cap: $552.41M
- Revenue: $N/A
- ROE: -48.22%
- ROIC: -50.92%
- Dividend Yield: N/A
About Olema Pharmaceuticals, Inc.
Olema Pharmaceuticals, Inc., a biopharmaceutical enterprise in the clinical development stage, is dedicated to discovering, advancing, and commercializing therapeutic solutions for women's oncology. Headquartered in San Francisco, California, the company was established in 2006 and rebranded from CombiThera, Inc. in March 2009. Its most promising investigational compound, OP-1250, an estrogen receptor (ER) antagonist and selective ER degrader, is presently undergoing Phase 1/2 clinical evaluations. This drug candidate is being assessed for its efficacy in managing recurrent, locally advanced, or metastatic breast cancer that expresses estrogen receptors but is negative for human epidermal growth factor receptor 2.
Olema Pharmaceuticals, Inc. Investment Frameworks
Invetso analyzes Olema Pharmaceuticals, Inc. (OLMA) across the following frameworks:
- Olema Pharmaceuticals, Inc. 10Y Growth Potential
- Olema Pharmaceuticals, Inc. Scenario Analysis
- Olema Pharmaceuticals, Inc. Risks & Opportunities
- Olema Pharmaceuticals, Inc. Economic Moat
- Olema Pharmaceuticals, Inc. Business Model
- Olema Pharmaceuticals, Inc. Management
- Olema Pharmaceuticals, Inc. SWOT Analysis
- Olema Pharmaceuticals, Inc. Porter's 5 Forces
- Olema Pharmaceuticals, Inc. PESTLE Analysis
- Olema Pharmaceuticals, Inc. ESG Analysis